Nilandron (Concordia Pharmaceuticals Inc.)


Welcome to the PulseAid listing for the Nilandron drug offered from Concordia Pharmaceuticals Inc.. This Androgen Receptor Antagonists [MoA],Androgen Receptor Inhibitor [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Concordia Pharmaceuticals Inc.
NON-PROPRIETARY NAME: Nilutamide
SUBSTANCE NAME: NILUTAMIDE
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Androgen Receptor Antagonists [MoA],Androgen Receptor Inhibitor [EPC]
ROUTE: ORAL
DOSAGE FORM: TABLET
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2013-07-15
END MARKETING DATE: 0000-00-00


Nilandron HUMAN PRESCRIPTION DRUG Details:

Item DescriptionNilandron from Concordia Pharmaceuticals Inc.
LABELER NAME: Concordia Pharmaceuticals Inc.
DEA SCHEDULE:
ACTIVE STRENGTH: 150(mg/1)
START MARKETING DATE: 2013-07-15
END MARKETING DATE: 0000-00-00
PRODUCT ID: 59212-111_648e10b6-b7f1-4be0-9fdc-e925e9fbba65
PRODUCT NDC: 59212-111
APPLICATION NUMBER: NDA020169

Other NILUTAMIDE Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
ANI Pharmaceuticals, Inc.Nilutamide
Concordia Pharmaceuticals Inc.Nilandron
sanofi-aventis U.S. LLCNilandron